DexCom stock
Price history
+39.53% over the period1 year: from $59.72 (November 13, 2025) to $83.33 (November 13, 2026), +39.53%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $83.33 |
| October 30, 2026 | $82.29 |
| September 30, 2026 | $86.29 |
| August 31, 2026 | $91.06 |
| July 31, 2026 | $83.45 |
| June 30, 2026 | $67.35 |
| May 29, 2026 | $73.74 |
| April 30, 2026 | $59.55 |
| March 31, 2026 | $62.80 |
| February 27, 2026 | $73.43 |
| January 30, 2026 | $73.04 |
| December 31, 2025 | $66.37 |
| November 28, 2025 | $63.47 |
| November 13, 2025 | $59.72 |
At a glance
The company
Designs and commercializes continuous glucose monitoring systems for diabetes and metabolic health management
Latest results
Quarter to September 30, 2026 · EPS $0.73 (estimate $0.67)
TickerLandia's take on DexCom
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 40 vs a median of 82 over its last 6 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 33 vs 29 (+14%) in a group of 10.
- Strong point: Profitability (80/100 in its group). Weak point: Earnings stability (45/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.00% from the 52-week high
Analysts · 29 analysts
Average target$98.58+18.30% vs. price
Buy 26 · Hold 3 · Sell 0 · Strong buy
TickerLandia Fingerprint: DexCom
Compared with similar companies: very high profitability.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh76
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 20.5 75 P/E (trailing 12 months) 32.8 60 Price/book 12.3 89 Price/sales 6.09 79 Forward P/E 26.6 78 Profitabilityvery high80
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 24.0% 85 Gross margin 63.4% 47 Net margin 19.4% 89 ROE 37.7% 95 ROA 11.1% 85 Earnings stabilityaverage45
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.3% 34 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthhigh67
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +2.60% 47 Revenue growth (year over year) +11.20% 66 Average revenue growth (3 years) +17.01% 89 Financial strengthaverage56
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.41 60 Current ratio 1.74 44 Debt/equitycounts in reverse: lower means more financial strength 0.55 50 Interest coverage 49.8 68 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong69
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −6.05% 31 Relative strength (6 months) +40.06% 92 1-year return +39.53% 81 Distance from 200-day average +10.99% 71 Riskaverage47
How much the price swings.
Metric Value Position in group Volatility (60 days) 36.2% 56 Beta (1 year) 0.73 52 Maximum drawdown (12 months) 22.6% 34
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
DexCom is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), DexCom's P/E today is 39.9, below the median of its last 6 fiscal years (82.5; between 31.8 and 253.3 from 2020 to 2025). DexCom's P/E (trailing 12 months): 32.8, +14% against the median of a group of 10 similar companies (28.7).
Compared with 10 similar companies
| Metric | DexCom | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 32.8 | Middle | |
| Forward P/E | 26.6 | High | |
| Operating margin | 24.0% | High | |
| ROE | 37.7% | High | |
| Debt/equity | 0.55 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: DexCom. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.31B
Latest quarter · Q2 2026
Net income
$249.1M
Latest quarter · Q2 2026
Quarterly net margin
19.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $31.08B
- P/E
- 32.8
- EPS
- $2.54
- Volume
- 3.01M
- Daily trading
- €366.95M
- Dividend yield
- 0.00%
How DexCom is changing
All resultsRevenue grew 19.3% a year on average over the last 5 years
Operating margin rose from 13.4% to 19.6%
Profits turn into cash: free cash flow equal to 114% of net income
Returns
DexCom returns
$1,000 invested in DexCom 5 years ago, on November 15, 2021, would be worth $519 today: −48.08% in total, −12.30% per year. This is the price return only: dividends are excluded.
| Period | DexCom | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −2.03% | −3.12% | $980 |
| 6 months | +42.27% | +1.58% | $1,423 |
| Year to date | +25.55% | +10.46% | $1,256 |
| 1 year | +39.53% | +12.23% | $1,395 |
| 3 years | −15.27% | +71.41% | $847 |
| 5 years | −48.08% | +61.48% | $519 |
| 10 years | +384.55% | +249.40% | $4,845 |
Over the last 6 months it has done better than 81% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
DexCom: technical analysis
DexCom shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 48.8% below its all-time closing high ($162.82, November 17, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 51
- Between 30 and 70
- vs 200-session average
- +10.99%
Support and resistance
Price areas where DexCom has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$92.46+10.96%2 touches, last on September 1, 2026
- Resistance$90.32+8.39%2 touches, last on November 5, 2026
- Resistance$88.19+5.83%2 touches, last on October 16, 2026
- Last price$83.33
- Support$82.58−0.91%2 touches, last on October 6, 2026
- Support$79.03−5.16%2 touches, last on July 16, 2026
- Support$75.59−9.29%4 touches, last on October 26, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.73
- Volatility (60 sessions, annualised)
- 36.2%
- Largest fall in the last year
- −22.61%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
DexCom: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for DexCom has been August: +8.40% on average, positive in 17 years out of 22. The weakest has been September: −4.26% on average, positive in 6 years out of 22. November, the current month, has been positive in 12 years out of 21 (+3.27% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +6.80% | +10.05% | 15 of 21 |
| February | +0.55% | −1.21% | 9 of 21 |
| March | +0.88% | +2.63% | 12 of 21 |
| April | +5.37% | +1.65% | 12 of 21 |
| May | +3.91% | +1.33% | 13 of 22 |
| June | +5.22% | +8.69% | 16 of 22 |
| July | −0.41% | −2.05% | 10 of 22 |
| August | +8.40% | +9.26% | 17 of 22 |
| September | −4.26% | −3.54% | 6 of 22 |
| October | −3.23% | −5.90% | 8 of 22 |
| November | +3.27% | +2.04% | 12 of 21 |
| December | +4.53% | +3.90% | 12 of 21 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
DexCom and its competitors
Its core activity is the design, development and sale of continuous glucose monitoring devices for people with diabetes and for metabolic health management. The range includes the Dexcom G7 and G7 15 Day integrated sensor, the Dexcom G6 system, and the Dexcom ONE+, which is intended to replace fingerstick testing in treatment decisions. The company also offers Stelo, a biosensor for adults with prediabetes or Type 2 diabetes who do not use insulin, together with Dexcom Share for remote monitoring and the Dexcom Follow app.
- Headquarters
- San Diego, United States
- Employees
- 11,000
- Founded
- 1999
- Chief executive
- Jacob Leach
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DexComDXCM | $31.08B | 24.0% | 32.8 | +42.27% |
| GE HealthCare TechnologiesGEHC | $37.54B | 13.8% | 17.6 | +34.14% |
| SterisSTE | $25.67B | 19.2% | 31.4 | +25.21% |
| Zimmer Biomet HoldingsZBH | $19.53B | 16.7% | 26.1 | +24.77% |
| Edwards LifesciencesEW | $61.61B | 28.8% | 61.6 | +31.65% |
| Boston ScientificBSX | $64.27B | 19.6% | 18.7 | −16.43% |
Same industry or related industries, similar size. Compare DexCom with its competitors · Full profile
